EMBO Molecular Medicine (Oct 2020)
Sarcoma treatment in the era of molecular medicine
- Thomas GP Grünewald,
- Marta Alonso,
- Sofia Avnet,
- Ana Banito,
- Stefan Burdach,
- Florencia Cidre‐Aranaz,
- Gemma Di Pompo,
- Martin Distel,
- Heathcliff Dorado‐Garcia,
- Javier Garcia‐Castro,
- Laura González‐González,
- Agamemnon E Grigoriadis,
- Merve Kasan,
- Christian Koelsche,
- Manuela Krumbholz,
- Fernando Lecanda,
- Silvia Lemma,
- Dario L Longo,
- Claudia Madrigal‐Esquivel,
- Álvaro Morales‐Molina,
- Julian Musa,
- Shunya Ohmura,
- Benjamin Ory,
- Miguel Pereira‐Silva,
- Francesca Perut,
- Rene Rodriguez,
- Carolin Seeling,
- Nada Al Shaaili,
- Shabnam Shaabani,
- Kristina Shiavone,
- Snehadri Sinha,
- Eleni M Tomazou,
- Marcel Trautmann,
- Maria Vela,
- Yvonne MH Versleijen‐Jonkers,
- Julia Visgauss,
- Marta Zalacain,
- Sebastian J Schober,
- Andrej Lissat,
- William R English,
- Nicola Baldini,
- Dominique Heymann
Affiliations
- Thomas GP Grünewald
- Max‐Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Marta Alonso
- Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, University of Navarra Pamplona
- Sofia Avnet
- Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli
- Ana Banito
- Pediatric Soft Tissue Sarcoma Research Group, German Cancer Research Center (DKFZ)
- Stefan Burdach
- Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München
- Florencia Cidre‐Aranaz
- Max‐Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Gemma Di Pompo
- Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli
- Martin Distel
- Children's Cancer Research Institute
- Heathcliff Dorado‐Garcia
- Department of Pediatric Oncology/Hematology, Charité‐Universitätsmedizin Berlin
- Javier Garcia‐Castro
- Cellular Biotechnology Unit, Instituto de Salud Carlos III
- Laura González‐González
- Cellular Biotechnology Unit, Instituto de Salud Carlos III
- Agamemnon E Grigoriadis
- Centre for Craniofacial and Regenerative Biology, King's College London
- Merve Kasan
- Max‐Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Christian Koelsche
- Institute of Pathology, Heidelberg University Hospital
- Manuela Krumbholz
- Department of Pediatrics, University Hospital
- Fernando Lecanda
- Division of Oncology, Adhesion and Metastasis Laboratory, Center for Applied Medical Research, University of Navarra
- Silvia Lemma
- Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli
- Dario L Longo
- Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR)
- Claudia Madrigal‐Esquivel
- Department of Oncology and Metabolism, University of Sheffield
- Álvaro Morales‐Molina
- Cellular Biotechnology Unit, Instituto de Salud Carlos III
- Julian Musa
- Max‐Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Shunya Ohmura
- Max‐Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich
- Benjamin Ory
- Université de Nantes, Inserm, U1238
- Miguel Pereira‐Silva
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra
- Francesca Perut
- Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli
- Rene Rodriguez
- Instituto de Investigación Sanitaria del Principado de Asturias
- Carolin Seeling
- Institute of Pathology, Ulm University
- Nada Al Shaaili
- Department of Oncology and Metabolism, University of Sheffield
- Shabnam Shaabani
- Department of Drug Design, University of Groningen
- Kristina Shiavone
- Department of Oncology and Metabolism, University of Sheffield
- Snehadri Sinha
- Department of Oral and Maxillofacial Diseases, University of Helsinki
- Eleni M Tomazou
- Children's Cancer Research Institute
- Marcel Trautmann
- Division of Translational Pathology, Gerhard‐Domagk‐Institute of Pathology, Münster University Hospital
- Maria Vela
- Hospital La Paz Institute for Health Research (IdiPAZ)
- Yvonne MH Versleijen‐Jonkers
- Department of Medical Oncology, Radboud University Medical Center
- Julia Visgauss
- Medical Center, Duke University
- Marta Zalacain
- Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR)
- Sebastian J Schober
- Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München
- Andrej Lissat
- University Children′s Hospital Zurich – Eleonoren Foundation, Kanton Zürich
- William R English
- Department of Oncology and Metabolism, University of Sheffield
- Nicola Baldini
- Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli
- Dominique Heymann
- Department of Oncology and Metabolism, University of Sheffield
- DOI
- https://doi.org/10.15252/emmm.201911131
- Journal volume & issue
-
Vol. 12,
no. 11
pp. 1 – 33
Abstract
Abstract Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult‐to‐treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
Keywords
